Enamel matrix derivative (EMD; Emdogain) vs placebo or control
PAL gain < 2 mm (dichotomous) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…
Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported.
1 finding from 1 review
- Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes1 year (time-points 1, 5 and 10 years planned)RR 0.53 [0.34, 0.82]6 studiesGRADE not reported